Jefferies initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $41 price target The firm, which believes BEAM-302 for Alpha-1 Antitrypsin Deficiency has shown “a superior profile” as a potential one-time therapy for a largely underdiagnosed genetic disease affecting about 100,000 U.S. patients, estimates $2.5B in peak sales for ‘302 to address both liver and lung manifestations. The firm also sees “modest value” for the BEAM-101 sickle cell disease program being currently in the stock, with a key near-term catalyst ahead, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics price target lowered to $46 from $48 at JPMorgan
- Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
- Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks
- Cathie Wood’s ARK Investment buys 491K shares of Beam Therapeutics today
- Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku